Q32 Bio Inc

QTTB

Company Profile

  • Business description

    Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32’s complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

  • Contact

    830 Winter Street
    WalthamMA02451
    USA

    T: +1 718 999-0232

    https://www.q32bio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    29

Stocks News & Analysis

stocks

A collection of our best stock opportunities

Our latest articles about where we see opportunities in the market.
stocks

Morningstar analyst reacts to Macquarie Group’s earnings

Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks

Undervalued ASX share showing progress in global efforts

More clarity on the path forward in the UK.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,966.703.200.04%
CAC 407,891.2490.361.16%
DAX 4024,251.50281.141.17%
Dow JONES (US)44,837.5664.36-0.14%
FTSE 1009,114.3332.890.36%
HKSE25,524.4537.68-0.15%
NASDAQ21,178.5870.270.33%
Nikkei 22540,674.55323.72-0.79%
NZX 50 Index12,936.4125.670.20%
S&P 5006,389.771.130.02%
S&P/ASX 2008,704.606.900.08%
SSE Composite Index3,609.7111.770.33%

Market Movers